Author: admin

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook

Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report

• In June 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
• In June 2025, Novartis Pharmaceuticals conducted a study planned a 6-month recruitment phase to enroll 40 subjects, followed by a 6-month treatment phase with monthly visits. Patients benefiting from the treatment could continue during a follow-up phase.
• In June 2025, Deciphera Pharmaceuticals LLC organized a Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
• DelveInsight’s Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
• The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.

Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs

• Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

• Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

• THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

• DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

The Gastrointestinal Stromal Tumors pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment.
• Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market.

Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight’s detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs

Gastrointestinal Stromal Tumors Companies

Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers

Scope of the Gastrointestinal Stromal Tumors Pipeline Report

• Coverage- Global
• Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
• Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Famitinib: Jiangsu Hengrui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nilotinib: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DS 6157: Daiichi Sankyo Company
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Gastrointestinal Stromal Tumors Key Companies
18. Gastrointestinal Stromal Tumors Key Products
19. Gastrointestinal Stromal Tumors- Unmet Needs
20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
22. Gastrointestinal Stromal Tumors Analyst Views
23. Gastrointestinal Stromal Tumors Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumor Pipeline strong with 25+ Companies driving therapeutic innovation: DelveInsight

DelveInsight’s, “Wet AMD Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet AMD pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet AMD pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Wet AMD Pipeline. Dive into DelveInsight’s comprehensive report today! @ Wet AMD Pipeline Outlook

Key Takeaways from the Wet AMD Pipeline Report

• In July 2025, Novartis Pharmaceuticals announced a study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
• In July 2025, Innostellar Biotherapeutics Co Ltd conducted a study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
• DelveInsight’s Wet AMD Pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Wet AMD treatment.
• The leading Wet AMD Companies such as Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Promising Wet AMD Pipeline Therapies such as NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.

Stay ahead with the most recent pipeline outlook for Wet AMD. Get insights into clinical trials, emerging therapies, and leading companies with Wet AMD @ Wet AMD Treatment Drugs

Wet AMD Emerging Drugs Profile

• ONS-5010: Outlook Therapeutics

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other approved retinal diseases. Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. Currently the drug is been registered for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• OPT-302: Opthea

OPT-302 is a soluble form of vascular endothelial growth factor receptor (VEGFR)-3 expressed as an immunoglobulin G1 (IgG1) Fc-fusion protein. It binds and neutralizes the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on their endogenous receptors, VEGFR-2 and VEGFR-3. Targeted inhibition of VEGF-C and VEGF-D can prevent blood vessel growth and vascular leakage, which contribute to the pathophysiology of retinal diseases including neovascular “wet” AMD. It is a first-in-class intravitreally administered biologic “trap” inhibitor of vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) currently being investigated in two concurrent Phase III pivotal registrational trials that will each enroll ~990 treatment naïve patients, in combination with two approved anti-VEGF-A treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial). OPT-302 has the potential to be positioned as complementary and agnostic with any combined anti–VEGF-A therapy for the treatment of wet AMD, a strategy intended to maximize the commercial opportunity for the therapy. Currently the drug in in Phase III stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• SYL1801: Sylentis

SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, by means of mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections . Currently the drug in in Phase II stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• BI 836880: Boehringer Ingelheim

BI 836880 is a humanized bispecific nanobody comprising blocking domains for VEGF and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2. By binding to VEGF and Ang2, BI 836880 inhibits tumor angiogenesis and vascularization and enhances the tumor microenvironment to support T-cell trafficking and function in the tumor. BI 836880 is currently being investigated in Phase II clinical studies for solid tumors and in Phase I/II clinical studies to treat wet AMD and non-small cell lung cancer.

The Wet AMD Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Wet AMD with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet AMD Treatment.
• Wet AMD Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet AMD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet AMD market

Explore groundbreaking therapies and clinical trials in the Wet AMD Pipeline. Access DelveInsight’s detailed report now! @ New Wet AMD Drugs

Wet AMD Companies

Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Wet AMD Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Wet AMD Treatment. Learn about new drugs, Wet AMD Pipeline developments, and key companies with DelveInsight’s expert analysis @ Wet AMD Market Drivers and Barriers

Scope of the Wet AMD Pipeline Report

• Coverage– Global
• Wet AMD Companies– Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Wet AMD Pipeline Therapies- NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.
• Wet AMD Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Wet AMD Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Wet AMD Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Wet AMD Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Wet Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. OPT-302: Opthea
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SYL1801: Sylentis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI 836880: Boehringer Ingelheim
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
21. Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
22. Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
23. Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
24. Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
25. Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
26. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wet AMD Pipeline Appears Robust With 60+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Septic Shock Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Septic Shock pipeline landscape. It covers the Septic Shock pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Septic Shock pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Septic Shock Pipeline. Dive into DelveInsight’s comprehensive report today! @ Septic Shock Pipeline Outlook

Key Takeaways from the Septic Shock Pipeline Report

• In June 2025, RWTH Aachen University announced aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival.
• DelveInsight’s Septic Shock Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Septic Shock treatment.
• The leading Septic Shock Companies such as Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences and others.
• Promising Septic Shock Pipeline Therapies such as Adrecizumab, OctaplasLG, Ringer-Acetate, Iloprost, Isotonic saline, FE 202158 and others.

Stay ahead with the most recent pipeline outlook for Septic Shock. Get insights into clinical trials, emerging therapies, and leading companies with Septic Shock @ Septic Shock Treatment Drugs

Septic Shock Emerging Drugs Profile

• VBI-S: Vivacelle Bio

VBI-S is the first product in a clinical trial treating an aspect of septic shock to have 100% efficacy in phase IIA results and achieve all of its endpoints in the past 20 years. The Phase III VBI-S trial is also fully funded. VBI-1 utilizes the same platform technology to treat hemorrhagic shock. VBI-1 cleared to start phase II. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. The drug is currently being investigated in the Phase III stage of development for the treatment of Septic Shock. 

• Adrecizumab: Adrenomed

Adrecizumab is a proprietary humanized monoclonal adrenomedulli-specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM and stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Binding of the monoclonal antibody Adrecizumab to bioactive adrenomedullin (bio-ADM) in the blood traps and stabilizes the peptide-hormone, resulting in increased ADM concentrations within the blood vessels. Adrecizumab is currently in Phase II clinical developmental stage for the treatment of septic shock and acute heart failure. Adrecizumab treatment significantly improved all clinically relevant endpoints such as reduction of vascular leakage and vasopressor demand, stabilization of the circulation, normalization of fluid balance and kidney function. In preclinical septic shock models, Adrecizumab reduced the mortality by 50%. The drug is currently being investigated in the Phase II stage of development for the treatment of Septic Shock.

The Septic Shock Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Septic Shock with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Septic Shock Treatment.
• Septic Shock Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Septic Shock Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Septic Shock market

Explore groundbreaking therapies and clinical trials in the Septic Shock Pipeline. Access DelveInsight’s detailed report now! @ New Septic Shock Drugs

Septic Shock Companies

Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences, and others.

Septic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Septic Shock Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Septic Shock Treatment. Learn about new drugs, Septic Shock Pipeline developments, and key companies with DelveInsight’s expert analysis @ Septic Shock Market Drivers and Barriers

Scope of the Septic Shock Pipeline Report

• Coverage- Global
• Septic Shock Companies- Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences and others.
• Septic Shock Pipeline Therapies- Adrecizumab, OctaplasLG, Ringer-Acetate, Iloprost, Isotonic saline, FE 202158 and others.
• Septic Shock Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Septic Shock Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Septic Shock Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Septic Shock Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Septic Shock: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Septic Shock– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VBI-S: Vivacelle Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Adrecizumab: Adrenomed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Septic Shock Key Companies
21. Septic Shock Key Products
22. Septic Shock- Unmet Needs
23. Septic Shock- Market Drivers and Barriers
24. Septic Shock- Future Perspectives and Conclusion
25. Septic Shock Analyst Views
26. Septic Shock Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/septic-shock-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Septic Shock Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Parkinson’s Disease Pipeline Insight, 2025” report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Parkinson’s Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Parkinson’s Disease Pipeline Outlook

Key Takeaways from the Parkinson’s Disease Pipeline Report

• In June 2025, Zomagen Biosciences Ltd. announced a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson’s Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
• In June 2025, MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals conducted a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson’s Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
• DelveInsight’s Parkinson’s Disease Pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
• The leading Parkinson’s Disease Companies such as Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.
• Promising Parkinson’s Disease Pipeline Therapies such as VTX3232, Rasagiline, Safinamide Methanesulfonate, Levetiracetam, CTC-413, CVXL-0107, Levodopa, Rotigotine, Istradefylline 20 mg or 40 mg, IPX054 100 mg and others.

Stay ahead with the most recent pipeline outlook for Parkinson’s Disease. Get insights into clinical trials, emerging therapies, and leading companies with Parkinson’s Disease @ Parkinson’s Disease Treatment Drugs

Parkinson’s Disease Emerging Drugs Profile

• Buntanetap: Annovis Bio

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.

• Tavapadon: Cerevel Therapeutics

Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyper activation of the dopamine receptors, which can lead to troublesome dyskinesias. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.

• Prasinezumab: Roche

Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson’s disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.

• Risvodetinib: Inhibikase Therapeutics, Inc

Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.

• GT 02287: Gain Therapeutics

GT-02287, is an allosteric regulator of GCase and is in development for the treatment of PD, with GBA1-PD as the lead indication. The orally administered, brain-penetrant small molecule restores the function of GCase. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced cellular stress in the endoplasmic reticulum, improved lysosomal function and mitochondrial function, reduced toxic glycosphingolipids, aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function. Currently, the drug is in Phase I trial for the treatment of Parkinson’s disease.

• NNI 362: Neuronascent

NNI-362 is Neuronascent’s patented oral therapeutic aimed at reversing age-related disorders by producing new neurons to replace those lost in chronic neurodegenerative disorders and aging. NNI-362 has a unique mechanism of action (MOA) that provides safety and selectivity specifically for neuron regeneration, and was discovered through Neuronascent’s proprietary phenotypic screening program using human neural progenitors. This MOA takes advantage of the neural progenitors already in the aged brain to promote new neurons and protect them from degeneration in chronic diseases of the aged, specifically Alzheimer’s disease. New neuron regeneration from neural progenitors is a physiologic process in the brain, yet with aging and neurodegenerative disease there begins a pathological insufficiency in generating new neurons that survive to functionality. Thus, NNI-362 is aimed at reversing age-related neuron loss and restoring cognitive function in AD patients, and should also be useful for other disorders of the elderly, including Parkinson’s disease and age-related hearing loss. Currently, the drug is in preclinical stage for the treatment of Parkinson’s disease.

The Parkinson’s Disease Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
• Parkinson’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market

Explore groundbreaking therapies and clinical trials in the Parkinson’s Disease Pipeline. Access DelveInsight’s detailed report now! @ New Parkinson’s Disease Drugs

Parkinson’s Disease Companies

Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Parkinson’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Parkinson’s Disease Treatment. Learn about new drugs, Parkinson’s Disease Pipeline developments, and key companies with DelveInsight’s expert analysis @ Parkinson’s Disease Market Drivers and Barriers

Scope of the Parkinson’s Disease Pipeline Report

• Coverage- Global
• Parkinson’s Disease Companies- Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune and others.
• Parkinson’s Disease Pipeline Therapies- VTX3232, Rasagiline, Safinamide Methanesulfonate, Levetiracetam, CTC-413, CVXL-0107, Levodopa, Rotigotine, Istradefylline 20 mg or 40 mg, IPX054 100 mg and others.
• Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Parkinson’s Disease Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Parkinson’s Disease Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Parkinson’s disease : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson’s Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Buntanetap: Annovis Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Risvodetinib: Inhibikase Therapeutics, Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GT 02287: Gain Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. NNI 362: Neuronascent
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson’s disease Key Companies
21. Parkinson’s disease Key Products
22. Parkinson’s disease – Unmet Needs
23. Parkinson’s disease – Market Drivers and Barriers
24. Parkinson’s disease – Future Perspectives and Conclusion
25. Parkinson’s disease Analyst Views
26. Parkinson’s disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Pipeline Appears Robust With 130+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Melanoma research. Learn more about our innovative pipeline today! @ Melanoma Pipeline Outlook

Key Takeaways from the Melanoma Pipeline Report

• In July 2025, Iovance Biotherapeutics Inc. announced a study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
• In June 2025, Merck Sharp & Dohme LLC announced a study is to learn if people who receive V940 with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
• In June 2025, Hoffmann-La Roche conducted a study will evaluate the efficacy and safety in participants with metastatic melanoma who developed brain metastases. Participants may or may not have received prior systemic treatment for metastatic melanoma [except treatment with v-raf murine sarcoma viral oncogene homolog B (BRAF) or mitogen-activated protein kinase (MEK) inhibitors]. Participants will receive oral doses of 960 mg vemurafenib twice daily until disease progression, unacceptable toxicity or consent withdrawal.
• DelveInsight’s Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
• The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
• Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.

Stay informed about the cutting-edge advancements in Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Melanoma Clinical Trials Assessment

Melanoma Emerging Drugs Profile

• IO102 IO103 : IO Biotech

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win® vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.

• mRNA 4157: Moderna Inc.

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. The drug is been developed jointly by Moderna & Merck. Currently being evaluated in the Phase III studies.

• MK-4830: Merck Sharp & Dohme LLC

MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Colorectal Cancer.

• BNT111: BioNTech SE

BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.

• TILT 123: TILT Biotherapeutics LLC

TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.

The Melanoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma Treatment.
• Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Melanoma market.

Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ Melanoma Unmet Needs

Melanoma Companies

IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.

Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Melanoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Melanoma Market Drivers and Barriers, and Future Perspectives

Scope of the Melanoma Pipeline Report

• Coverage- Global
• Melanoma Companies- IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
• Melanoma Therapies– Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
• Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Melanoma Pipeline on our website @ Melanoma Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. IO102 IO103 : IO Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MK-4830: Merck Sharp & Dohme LLC
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. TILT 123: TILT Biotherapeutics LLC
15. Inactive Products
16. Melanoma Key Companies
17. Melanoma Key Products
18. Melanoma- Unmet Needs
19. Melanoma- Market Drivers and Barriers
20. Melanoma- Future Perspectives and Conclusion
21. Melanoma Analyst Views
22. Melanoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/melanoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Melanoma Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight